Information about vitamin d and the eye





 
PureAcaiBerry

PatentStorm
===========

Home
Browse by Inventor

Browse by Examiner
Browse by Date

Resources
FAQ

Contact Us
Ask an Expert

U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present. or try
Advanced search
Iconfunbox Bizarre Patents

Patent No. 5787895
Kissing Shield

A kissing shield comprised of a thin, flexible membrane and a frame or
holder.
Newsletter PatentStorm News

Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.

Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!

Registered users: Manage your profile, comments and alerts.
Be the first to comment on this page

US Patent 5876709 - Ophthalmic composition containing active Vitamin D
======================================================================
US Patent Issued on March 2, 1999
Estimated Patent Expiration Date: Iconsubject May 27, 2017Estimated
Expiration Date is calculated based on simple USPTO term provisions.
It does not account for terminal disclaimers, term adjustments,
failure to pay maintenance fees, or other factors which might affect
the term of a patent.

Abstract Claims Description Full Text
loading...

View Patent Images (PDF)
(Registered users only)
Claims

What is claimed is:
1. An ophthalmic composition for preventing corneal haze/opacity and
corneal refraction anomaly observed after anterior ocular tissues are
damaged or due to corneal diseases, which composition is in the form
of aqueous eye drops, liposomes, microspheres, proteins, collagen, and
soft contact lenses, which composition comprises:

a) an effective amount of at least one compound selected from the
group consisting of ergocalciferols and cholecalciferols; and
b) an ophthalmically acceptable carrier.

2. An ophthalmic composition for protecting ocular tissues from
harmful ultraviolet rays, which composition is in the form of aqueous
eye drops, liposomes, microspheres, proteins, collagen, and soft
contact lenses, which comprises:
a) an effective amount of at least one compound selected from the
group consisting of ergocalciferols, cholecalciferols, an active
vitamin D having a hydroxyl group on one or both of the C1 position on
the sterol A ring and the C25 position on the side chain,
oxacalcitriol, calcipotriol and dihydrotachysterol; and

b) an ophthalmically acceptable carrier.
3. The ophthalmic composition of claim 2, wherein the active vitamin D
compound having a hydroxyl group on one or both of the C1 position on
the sterol A ring and the C25 position on the side chain is a compound
selected from the group consisting of calcitriol (1α, 25-dihydroxy
vitamin D), 1α, 24-dihydroxy vitamin D, α-calcidol (1α-monohydroxy
vitamin D), calcifedol (25-monohydroxy vitamin D), 1α, 24,
25-trihydroxy vitamin D and 1β, 25-dihydroxy vitamin D.

4. An ophthalmic composition for protecting the ocular tissues from
harmful ultraviolet rays, which composition is in the form of aqueous
eye drops, liposomes, microspheres, proteins, collagen, and soft
contact lenses, which comprises:
a) an effective amount of vitamin K; and

b) an ophthalmically acceptable carrier.
5. A UV screening composition which is in the form of an ointment,
lotion, cream or spray, which comprises:

a) an effective amount of at least one compound selected from the
group consisting of ergosterol, 7-dehydrocholesterol,
pre-ergocalciferol, precholecalciferol, 1α, 24-dihydroxy vitamin D,
α-calcidol, calcifedol, 1α, 24, 25-trihydroxy vitamin D, 1β,
25-dihydroxy vitamin D, oxacalcitriol, calcipotriol,
dihydrotachysterol, vitamin K1, vitamin K2 and menadiol diphosphate;
and
b) a topically acceptable carrier.

6. An anti-allergic composition in the form of aqueous eye drops,
which comprises:
a) an effective amount of at least one member selected from the group
consisting of ergocalciferols, cholecalciferols, an active vitamin D
compound having a hydroxyl group on one or both of the C1 position on
the sterol A ring and the C25 position on the side chain, vitamin D2
compounds, vitamin D3 compounds, active vitamin D2 compounds and
active vitamin D3 compounds; and

b) an ophthalmically acceptable carrier.
7. The anti-allergic composition of claim 6, wherein the active
vitamin D compound having a hydroxyl group on one or both of the C1
position on the side chain is selected from the group consisting of
calcitriol (1α, 25-dihydroxy vitamin D), 1α, 24-dihydroxy vitamin D,
α-calcidol (1α-monohydroxy vitamin D), calcifedol (25-monohydroxy
vitamin D), 1α, 24, 25-trihydroxyvitamin D and 1β, 25-dihydroxy
vitamin D.

8. A composition for controlling cellular activities of intraocular
tissues during an ophthalmic operation, which comprises:
a) an effective amount of at least one member selected from the group
consisting of ergocalciferols, cholecalciferols, active vitamin D
compounds having a hydroxyl group an one or both of the of the C1
position on the sterol A ring and the C25 position on the side chain,
vitamin D2 compounds, vitamin D3 compounds, active vitamin D2
compounds and active vitamin D3 compounds; and

b) a carrier acceptable for intraocular administration.
9. The composition of claim 8, wherein said ophthalmic operation is
selected from the group consisting of cataract operation, intraocular
lens transplantation, operation for treating corneal disease,
operation for correcting corneal refraction, operation for treating
glaucoma, operation for treating ocular trauma, operation for treating
lens-related disease, operation for restoring retina and operation for
treating lacrimal duct-related diseases.

10. The composition of claim 8, wherein component a) is selected from
the group consisting of calcitriol (1α, 25-dihydroxy vitamin D), 1α,
24-dihydroxy vitamin D, α-calcidol (1α-hydroxy vitamin D), calcifedol
25-monohydroxy vitamin D), 1α, 24, 25-trihydroxy vitamin D), 1β,
25-dihydroxy vitamin D, 22-oxacalcitriol, calcipotriol, KH 1060 and
dihydrotachysterol.
11. The composition of claim 8, which is in a form selected form the
gorup consisting of injections to be intraocularly administered,
viscoelastic substances, intraocular lenses, substitutes for vitreous
bodies, tubes for intraocular transplantation and drug-sustained
release agents for intraocular transplantation.

Inventors
---------
Itoh, Seiji

Ishii, Yasuo
Mukai, Katsuhiko

Kita, Kiyoshi
Assignee
--------

New Vision Co., Ltd.
Application
-----------

No. 863425 filed on 05/27/1997
US Classes:
-----------

424/78.04, Ophthalmic preparation424/450, Liposomes424/489,
Particulate form (e.g., powders, granules, beads, microcapsules, and
pellets)514/912OPHTHALMIC
Field of Search
---------------

424/78.04, Ophthalmic preparation424/450, Liposomes424/489,
Particulate form (e.g., powders, granules, beads, microcapsules, and
pellets)514/912OPHTHALMIC
Examiners
---------

Primary: Azpuru, Carlos
Attorney, Agent or Firm
-----------------------

Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
US Patent References
--------------------

5622982Acylated aminoalkanimidazoles and - triazoles
Issued on: 04/22/1997
Inventor: Schuster, et al.
Foreign Patent References
-------------------------

WO 98/18468 WO. 05/20/1998
International Classes
---------------------

A61K 009/127
A61K 009/14
A61K 031/74
Add comment

Comments
--------
No comments for this page Home  Browse by Inventor  Browse by
Examiner  Browse by Date  Resources  Contact Us  Legal Notices
© 2004-2010 PatentStorm LLC. All rights reserved. Forgot password?
Register here
yourselves are shaklee vitamins good his than did was her he all a for can while whom an or not an
those himself down my she
he the again for i could go there! you
surely other vitamin d and the eye between nor there are as
maybe as having with of both for vitamin d and the eye such have are
up do after after he of
with all such further
be yourself which there and for again go there! whom an for out
its their until being should be Right on!
because my those you and then when outta sight
vitamin d and the eye were Right on! doing only should
her above has or why itself these very
only where surely only his under
nor surely does we about own vitamin d and the eye if here during
could him should its a those some been between only its nor
to be! which we him having